Clinical trials: Metastatic Colorectal Cancer (CRC)
Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
This randomized phase II trial studies how well combination chemotherapy and bevacizumab with or without CBP/beta-catenin antagonist PRI-724 (PRI-724) works in treating patients with newly diagnosed colorectal cancer that has…
- Conditions
- Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- PRIMIER (NCT02413853)
- Testing
- CBP/beta-catenin Antagonist PRI-724, Bevacizumab, Leucovorin Calcium
- Where
- United States
- Sponsor
- University of Southern California
Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM)
Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling
The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with…
- Conditions
- Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM), Circulating Tumor DNA (ctDNA)
- Trial name
- ctDNA TAP (NCT07310537)
- Testing
- Blood Collection - TAP® Device, Blood Collection - Venous
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
Solid Tumor, Metastatic Colorectal Cancer
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
The primary purpose of this study is to find the highest tolerated dose of the study drugs: capecitabine, oxaliplatin, bevacizumab, and dasatinib given in combination to subjects with advanced solid tumors.
- Trial name
- XAD (NCT00920868)
- Testing
- dasatinib, bevacizumab, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Herbert Hurwitz, MD
Metastatic Colorectal Cancer (CRC)
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.
- Trial name
- NCT06887218
- Testing
- Regorafenib (BAY 73-4506), 5FU/LV, Bevacizumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Colorectal Cancer
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.
- Trial name
- NCT00717990
- Testing
- Capecitabine, Bevacizumab, Irinotecan
- Where
- Greece
- Volunteers
- 15 people
- Sponsor
- University Hospital of Crete
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Colorectal Cancer Liver Metastasis
Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM
This study is a prospective, multicenter, randomized controlled clinical trial to evaluate the safety and efficacy of polyvinyl alcohol sodium acrylate embolization microspheres and HepaSphere Microspheres loaded with irinotecan…
- Trial name
- NCT06021015
- Testing
- Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）, Irinotecan and HepaSphere Microspheres
- Volunteers
- 72 people
- Sponsor
- Zhongda Hospital
Colorectal Carcinoma
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV).
- Trial name
- NCT00176774
- Testing
- Irinotecan, 5-Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Colorectal Carcinoma, Neuropathy
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum.
- Trial name
- ASIST (NCT05322590)
- Testing
- BXQ-350
- Where
- 12 sites in United States
- Volunteers
- 195 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
ColoRectal Cancer, Liver Metastases
Simultaneous Resection of Colorectal Cancer With Synchronous Liver Metastases
Synchronous colorectal cancer with liver metastases, defined as the diagnosis of a primary colorectal tumour and liver metastases within 12 months, is a common problem faced by colorectal and hepatobiliary surgeons.(Adam) The…
- Conditions
- ColoRectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Surgery
- Trial name
- RESECT (NCT02954913)
- Testing
- Simultaneous Resection
- Where
- 2 sites in Canada
- Volunteers
- 41 people
- Sponsor
- Hamilton Health Sciences Corporation
Colorectal Cancer
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have metastatic or locally recurrent colorectal cancer.
- Trial name
- NCT00005085
- Testing
- becatecarin
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms, Neoplasm Metastasis
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.
- Trial name
- NCT00921661
- Testing
- AVE0005 (aflibercept)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Sanofi
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI…
- Trial name
- NCT04799431
- Testing
- Neoantigen Vaccine with Poly-ICLC adjuvant, Retifanlimab
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, SGLT-2 Inhibitor
Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer
Colorectal cancer (CRC), ranking third in incidence among men and second in women globally with third-highest mortality in the US, remains a major health challenge despite multimodal therapies, particularly for advanced-stage…
- Trial name
- NCT07076823
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
Malignant Neoplasms, Metastatic Cancer
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.
- Trial name
- NCT05315180
- Testing
- BPI-421286
- Where
- 5 sites in China
- Volunteers
- 80 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Elderly Metastatic Colorectal Cancer Patients
First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
Oxaliplatin-based doublets plus bevacizumab are standard first-line therapy options for patients (pts) with metastatic colorectal cancer (mCRC).
- Trial name
- COBRA (NCT03451370)
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Metastatic Colorectal Cancer
Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy.
- Trial name
- SAFE (NCT00862342)
- Testing
- Bevacizumab (Avastin)
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Asan Medical Center
Colorectal Cancer, Advanced/Metastatic Solid Tumor
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with…
- Conditions
- Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM
- Trial name
- NCT07878988
- Testing
- LTZ-232
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- LTZ Therapeutics, Inc.
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company